Effects of switching from <scp>MiniMed</scp>™ <scp>640G</scp> to <scp>770G</scp> on continuous glucose monitoring metrics and <scp>DTR</scp>‐<scp>QOL</scp> scores: An observational study of Japanese people with type 1 diabetes mellitus
Use of the MiniMed™ 770G improved continuous glucose monitoring metrics. However, treatment satisfaction decreased, probably due to the increased frequency of blood glucose monitoring necessary to maintain auto mode.
Authors
- Toshiki Kogai (ORCID: https://orcid.org/0009-0000-3126-3311)
- Akihiko Ozaki (ORCID: https://orcid.org/0000-0003-4415-9657)
- Hirotaka Watada (ORCID: https://orcid.org/0000-0001-5961-1816)
- Yuya Nishida (ORCID: https://orcid.org/0000-0002-8396-423X)
- Junko Sato (ORCID: https://orcid.org/0000-0002-9784-5362)
- Fuki Ikeda (ORCID: https://orcid.org/0000-0002-7638-6056)
- Mami Koshibu
- Hajime Yasuda (ORCID: https://orcid.org/0000-0002-2896-7737)
- Tatsuhiro Ayame
- Eri Takagi (ORCID: https://orcid.org/0009-0002-4306-8809)
Institutions
- Juntendo University (JP)
Publication Details
- Journal
- Journal of Diabetes Investigation
- Published
- 2024-11-08
- DOI
- https://doi.org/10.1111/jdi.14350
- Citations
- 2
- Primary Topic
- Diabetes Management and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.72
Funders
- Eli Lilly and Company
- AstraZeneca
- Sanofi
- Kowa Company
- Kissei
- Boehringer Ingelheim Japan
- Novo Nordisk
- Astellas Pharma
- Teijin Pharma
- Mitsubishi Tanabe Pharma Corporation
- Ono Pharmaceutical
- Daiichi Sankyo Company
- Daiichi Sankyo Europe